Our preliminary study also demonstrated that addition of LXR agonist could inhibit lung cancer cells (resistance to gefitinib) proliferation, induce cancer cells’ apoptosis and significantly increase cancer cells’ sensitivity to gefitinib by the inhibition of AKT phosphorylation [12]. Here, AKT1 is linked to cancer.